{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreigidcewykk2nje2n2de6hefozu6a4alsjatflzggwajcmifyfybby",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mnjnc7in7le2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreihpjhbtb6vl6psji57kvftw7dunpqvjkon5yeygrisai6xgf5pole"
    },
    "mimeType": "image/jpeg",
    "size": 41334
  },
  "path": "/2026/06/04/otsuka-kidney-drug-voyxact-study-results/?utm_campaign=rss",
  "publishedAt": "2026-06-04T19:59:34.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "Pharma",
    "biotechnology",
    "chronic diseases",
    "Pharmaceuticals",
    "STAT+"
  ],
  "textContent": "Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the benefit was less than expected.",
  "title": "STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trial",
  "updatedAt": "2026-06-04T20:38:07.000Z"
}